A 48-Year-Old Immunocompetent Female Resident of Southern Florida with Confirmed Reinfection with P.1 (Gamma) Variant of SARS-CoV-2.
PMID: 35041639
2022
The American journal of case reports
Abstract: Whole-genome sequencing (WGS) of viral RNA from the patient's second infection confirmed that the viral strain was P.1 variant containing the E484K spike protein substitution.
Conclusion: WGS of viral RNA from the patient's second infection showed the viral strain to be P.1 variant containing the E484K spike protein substitution, which is considered a substitution of therapeutic concern (SOTC) by the CDC.
Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
Introduction: In the spike protein of the B.1.1.28 strain, there are eleven mutations, including L18F, T20N, P26S, D138Y, R190S, H655Y, T1027I, D614G, K417T, E484K, and N501Y.
Introduction: Strain B.1.351 contains nine mutations within spike protein, including the L18F, D80A, D215G, R246I, K417N, Table: E484K
Unique Evolution of SARS-CoV-2 in the Second Large Cruise Ship Cluster in Japan.
Introduction: This extensive molecular surveillance of the virus has enabled researchers to identify critical mutations that might contribute to higher transmissibility or immune escape, such as D614G, N501Y, and E484K amino acid substitutions in the spike (S) protein.
SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression.
Abstract: SARS-CoV-2 was identified as variant Alpha (PANGO lineage B.1.1.7) with mutation S:E484K.
Result: Interestingly, 23012G > A (S:E484K) was already technically fixed (VAF > 0.95) at the first time point, but its frequency decreased at T2 and T3 going down to 0.49-0.72.
Result: SARS-CoV-2 was classified as an Alpha variant (Phylogenetic Assignment of Named Global Outbreak Lineages-PANGO-lineage B.1.1.7), similar to the consensus sequences of dominant contemporaneous isolates circulating by the same
Discussion: Interestingly, E484K was already fixed at the first time point, but waned at the second and third time points.
Discussion: The S:E484K mutation alters antibody recognition.
Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents.
Introduction: Different spike mutations emerged and became dominant in the emerged variants of concern (VOC), such as the representative mutations D614G, N501Y, E484Q/K, L452R, P681R in the Alpha, Beta, Gamma, and Delta variants.
Discriminatory Weight of SNPs in Spike SARS-CoV-2 Variants: A Technically Rapid, Unambiguous, and Bioinformatically Validated Laboratory Approach.
Introduction: The Beta variant, discovered a few days after the Alpha in samples collected between March and November 2020, also carries the N501Y mutation (phylogenetically not related to the Alpha variant) and other peculiar substitutions in the S gene:D80A, D215G, E484K, N501Y, and A701V.
Introduction: The Gamma variant emerged in February 2020 and is associated with the E484K, K417N, N501Y, and H655Y mutations in the S gene.
Introduction: The Iota variant has six mutations on the spike gene (L5F
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.
Abstract: Some of the pivotal mutations such as N501Y and E484K in the receptor-binding domain (RBD) detected in B.1.1.7 (Alpha), B.1.351 (Beta) and P.1 (Gamma) are now present within the Mu variant.
Introduction: The Spike of Mu accumulated the following mutations: insertion in 146N, T95I, Y144T and Y145S, in the N-terminal domain (NTD); R346K, E484K, N501Y in the receptor-binding domain (RBD) and P681H at the S1/S2 interface.
Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.
Discussion: Both the beta and theta variants contain N501Y and E484K mutations in the S-protein, which enhanced the affinity of ACE2, and immune sera showed decreased activity when the mutations, including N501Y and E484K.
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Figure: (a, b) Binding of the antibodies to the RBD carrying the individual mutations (N501Y, N439K, E484K, K417N) and RBD with triple mutation N501Y/E484K/K417N were analysed.
Figure: ACE2 is shown in a green cartoon model, RBD as a grey surface model, mutations N439K (within AX677 binding site) and E484K (wi
Discussion: The antibodies were oblivious to the E484K mutation, which has been recently shown to endow the S-typed VSV pseudovirus with resistance to several human convalescent sera.
Multiplexed Lab-on-a-Chip Bioassays for Testing Antibodies against SARS-CoV-2 and Its Variants in Multiple Individuals.
Abstract: The concentrations of antibodies against RBD, D614G, N501Y, E484K, and L452R/E484Q-mutants after two doses of vaccines are 6.6 +- 3.6, 8.7 +- 4.6, 3.4 +- 2.8, 3.8 +- 2.8, and 2.8 +- 2.3 ng/mL, respectively.
Abstract: This suggests that neutralizing activities against N501Y, E484K, and L452R/E484Q-mutants were less effective than RBD and D614G-mutant.
Introduction: Each test can detect six targets (RBD, D614G, N501Y,
SARS_CoV_2 mutation literature information.
PMID: 
2022
The American journal of case reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT